Form D · Pharmaceuticals
Cyclarity Therapeutics, Inc.
Novato, CA · CIK 0001794705
Offering snapshot reported Dec 30, 2024 · SEC filing
- Reported sold
- $10.3M Offering amount: $12.8M
- Investors reported
- 19 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 16, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 30, 2024 | Initial | $10,288,140 | No comparison | 19 | SEC filing |
| Sep 7, 2021 | Initial | $3,519,169 | No comparison | Not reported | SEC filing |
| Nov 25, 2019 | Initial | $1,450,001 | No comparison | 9 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-533653
Includes the issuance of shares of preferred stock upon conversion of simple agreements for future equity and a convertible note.
Source: Form D, filed Dec 30, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Michael Kope | Director, Executive |
| Matthew O'connor | Director, Executive |
| Frank Schueler | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
8001 Redwood Blvd
Novato, CA, 94945
Novato, CA, 94945